Media centre

All Group media enquiries should be directed to
Vanessa Maydon, Corporate Affairs Director.

Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG

Tel: +44 (0)20 7661 3325
Mob: +44 (0)7802 961 902
Email: Vanessa Maydon

Press releases

Sebia
2 June 2014

Cinven to sell Sebia

European private equity firm Cinven today announces that it has entered into exclusive negotiations with a consortium led by Montagu Private Equity and Astorg Partners for the sale of Sebia ('the Company'), the in-vitro diagnostics protein testing business, for an undisclosed consideration. The transaction will generate a 2.4x return on Cinven's original investment.

During Cinven's ownership and under CEO Benoit Adelus' team leadership Sebia has expanded its operations into the US and emerging markets resulting in significant revenue increase comprising 21% and 23% of total revenue respectively. As a result of the growth initiatives undertaken, Sebia is now a clear global leader within the in-vitro diagnostics market.

The Company also launched major products such as a diabetes test and is in the process of launching a new generation of Capillary instrument - which provide strong future earnings growth.

The Cinven Healthcare team had previously invested in the in-vitro diagnostics sector through Phadia, the in-vitro diagnostics allergy testing business, in 2007 which was subsequently sold to Thermo Fisher Scientific, Inc. in 2011 generating a 3.4x multiple on Cinven's original investment. This previous experience combined with Cinven's strong network in the French market, enabled Cinven to originate and invest in Sebia.

Nicolas Paulmier, Partner at Cinven, commented:
"Our investment in Sebia illustrates clearly our 'repeat play' investment strategy.  Our Healthcare team had invested in Phadia, a highly successful in-vitro diagnostics business. This provided us with the industry knowledge and insight to enable our French and healthcare teams to then identify the Sebia opportunity, back a fantastic management team and invest subsequently in the business. Our investment strategy for Sebia was the same as the one we had already successfully implemented at Phadia, focused on US expansion, emerging market growth, and a game changing new product launch. We wish Benoit and his team at Sebia every success under new ownership as the Company embarks on its next phase of growth."

"Our realisation of Sebia in France follows the highly successful realisation of Numericable earlier this year initially through an IPO and then the deal with SFR, generating an IRR of 160%."

Benoit Adelus, Chief Executive of Sebia, commented:
"Cinven's previous experience in the field of in-vitro diagnostics, through their investment in Phadia, contributed to establish a very good relationship. During Cinven's shareholding we got their full support to enter new areas such as diabetes and to strengthen our positioning worldwide."

Completion of the transaction is subject to consultation with Sebia's Works Council and satisfactory clearance from relevant competition and regulatory authorities.

Latham & Watkins acted as exclusive advisor to Cinven.

Portfolio company videos

 Clinical Trials

Bioclinica

Clinical Trials

 Travel services provider

Hotelbeds Group

Travel services provider

 Truck component manufacturer

Jost

Truck component manufacturer

 Footwear and accessories retailer

Kurt Geiger

Footwear and accessories retailer

 Contract research organisation

Medpace

Contract research organisation

 Electronic security and alarm systems

Pronet

Electronic security and alarm systems

 Property valuation and advisory services

Tinsa

Property valuation and advisory services

 Ufinet is a neutral telecom operator.

Ufinet

Ufinet is a neutral telecom operator.

 Business services software

Visma

Business services software

Media contacts

Cinven

Vanessa Maydon
Corporate Affairs Director
Tel : +44 (0)20 7661 3325
Mob : +44 (0)7802 961 902
Email : Vanessa Maydon

Clare Bradshaw
Communications Manager
Tel : +44 (0)20 7667 3248
Mob : +44 (0)7881 918 967
Email : Clare Bradshaw

UK - FTI Consulting

Edward Bridges
Tel : +44 (0)20 7269 7147
Mob : +44 (0)7768 216 607
Email : Edward Bridges

Stephanie Ellis
Tel : +44 (0)20 3727 1173
Mob : +44 (0)7890 543 056
Email : Stephanie Ellis

France โ€“ FTI Consulting

Guillaume Granier
Tel : +33 (0)1 47 03 68 61
Mob : +33 (0)6 32 65 79 28
Email : Guillaume Granier

Caroline Guilhaume
Tel : +33 (0)1 47 03 68 17
Mob : +33 (0)6 38 91 88 51
Email : Caroline Guilhaume

Germany - FTI Consulting

Lutz Golsch
Tel : +49 (0)69 920 37 110
Mob : +49 (0)173 651 7710
Email : Lutz Golsch

Daniel Herbert
Tel : +49 (0)69 920 37 183
Mob : +49 (0)151 122 63834
Email : Daniel Herbert

US - Joele Frank

Jonathan Keehner
Tel : +1 212.355.4449
Mob : +1 917 589 2073
Email : Jonathan Keehner

Julie Oakes
Tel : +1 212.355.4449
Mob : +1 917 574 7263
Email : Julie Oakes

Spain โ€“ Groupo Albion

Alejandra Moore Mayorga
Tel : +34 91 531 23 88
Email : Alejandra Moore Mayorga

Sofia Garcia
Tel : +34 91 531 23 88

Italy โ€“ Community Group

Roberto Patriarca
Tel : +39 02 89 40 42 31
Mob : +39 335 65 09 568
Email : Roberto Patriarca

Marco Pedrazzini
Tel : +39 02 89 83 66 21
Mob : +39 347 0369 222
Email : Marco Pedrazzini